Optical physiologic sensor devices

ABSTRACT

Physiologic sensors and methods of application are described. These sensors function by detecting recently discovered variations in the spectral optical density at two or more wavelengths of light diffused through the skin. These variations in spectral optical density have been found to consistently and uniquely relate to changes in the availability of oxygen in the skin tissue, relative to the skin tissue&#39;s current need for oxygen, which we have termed Physiology Index (PI). Current use of blood gas analysis and pulse oximetry provides physiologic insight only to blood oxygen content and cannot detect the status of energy conversion metabolism at the tissue level. By contrast, the PI signal uniquely portrays when the skin tissue is receiving ‘less than enough oxygen,’ just the right amount of oxygen,′ or ‘more than enough oxygen’ to enable aerobic energy conversion metabolism. The PI sensor detects one pattern of photonic response to insufficient skin tissue oxygen, or tissue hypoxia, (producing negative PI values) and a directly opposite photonic response to excess tissue oxygen, or tissue hyperoxia, (producing positive PI values), with a neutral zone in between (centered at PI zero). Additionally, unique patterns of PI signal response have been observed relative to the level of physical exertion, typically with a secondary positive-going response trend in the PI values that appears to correspond with increasing fatigue. The PI sensor illuminates the skin with alternating pulses of selected wavelengths of red and infrared LED light, then detects the respective amount of light that has diffused through the skin to an aperture located a lateral distance from the light source aperture. Additional structural features include means of internally excluding light from directly traveling from the light emitters to the photodetector within the sensor. This physiology sensor and methods of use offer continuous, previously unavailable information relating to tissue-level energy conversion metabolism. Several alternative embodiments are described, including those that would be useful in medical care, athletics, and personal health maintenance applications.

CROSS-REFERENCE

This application claims priority to U.S. patent application Ser. No.15/332,230 filed Oct. 24, 2016 which claims the benefit of U.S.Provisional Application No. 62/246,374, filed Oct. 26, 2015, entitledOPTICAL PHYSIOLOGIC SENSORS AND METHODS which applications areincorporated herein by reference.

BACKGROUND

One of the primary life-dependencies of humans is continuous delivery ofoxygen by the lungs and blood circulatory system to all tissues of thebody in sufficient quantity to maintain aerobic metabolism; thus,avoiding tissue injury from too little, or too much oxygen. Toapproximate this information, clinicians must mentally correlatemeasurements of breathing gas oxygen fraction, breathing rate, heartrate, cardiac output, blood hemoglobin level, arterial bloodhemoglobin-oxygen saturation (“blood gas,” or SaO₂), and pulse oximetry(SpO₂), along with a subjective evaluation of arterial blood flowdistribution. While each of these separate measurements are known toprovide significant information, this currently available data, evenwith expert analysis, cannot provide the “bottom-line” tissue-levelinsight that has long been missing. Clinicians have long known that itis the tissue of vital organs, especially the brain, that is at risk ofbeing injured; not the blood. The recently introduced Lumee™ sensor(Profusa), measures the oxygen level in tissue, but cannot indicatewhether there is enough, or too much, oxygen. Also, the new sweatlactate sensor from Kenzen indicates when the skin is anaerobic, butcannot work when there is no sweat production and does not sense whentoo much oxygen is present. Without accurate, objective tissue-levelinformation, the limitations of blood and tissue oxygen metrics, humansensory misperceptions, and subjective clinician assessment errors inthis critical part of medical care can inadvertently result in permanentvital organ tissue damage and possibly death. Thus, there is an unmetneed in critical care medicine for an objective, reliable, andpreferably non-invasive indicator of oxygen-related energy conversionmetabolism at the tissue level.

Personal need and desire for basic physiologic information is also foundin many areas of normal living, such as maintenance of general healthand conditioning, obesity weight loss exercise, maintaining safety inrecreational and workplace activities, and athletic training andperformance. While “medical device-like” vital sign monitoring deviceshave recently been re-packaged into consumer-friendly “activity tracker”devices, the same limitations remain with respect to their delivery ofphysiologic information.

SUMMARY

In one aspect of the disclosure, physiology index (PI) sensors with asuitable power source are configured to use about 660+/−10 nm and about850+/−10 nm LED emitters. These two wavelength regions have been found,empirically, to produce the most pronounced divergence of the respectiveoptical signal intensity from 850+/−10 nm light, relative to asimultaneously obtained signal intensity produced from 660+/−10 nmlight. In the case of insufficient skin tissue oxygen supply, such ascan be induced by briefly breathing nitrogen gas, the optical signalintensity from the 660+/−10 nm light, after it has diffused through skintissue, has been found to diminish in intensity more rapidly than thesignal from the 850+/−10 nm light after it has similarly diffusedthrough skin tissue. Conversely, the presence of excessive tissue oxygensupply relative to skin tissue oxygen need and tolerance, such as can beinduced by briefly breathing pure oxygen, has been found to produce aprogressive, uniquely diverging optical signal from 850+/−10 nm light,relative to a simultaneously obtained signal produced from 660+/−10 nmlight, with the optical signal intensity from the 850+/−10 nm lightdiminishing more rapidly than the signal from the 660+/−10 nm light,likely corresponding with progressively increased presence of productsof reactive oxygen species (ROS) chemical reactions within the skin,such as with intake of increased oxygen fraction in the breathing gas,or at the end of an extended exercise activity. It should be noted thatsimilar, but typically less pronounced, photonic responses have beenfound present within the spectral regions on either side of theabove-listed center wavelengths of light, and that the abovespecification is exemplary only, and not intended to be exclusive, andis provided to be illustrative of the general concepts involved. Itshould also be noted that the disclosed PI signal is not a directmeasurement of oxygen in the skin or in the blood. Rather, it isdisclosed as an index of whether the current oxygen delivery rate to theskin tissue is less than, just right, or more than needed by the skintissue for aerobic energy conversion at the skin tissue's currentacclimation.

In another aspect of the disclosure, the two or more selectedwavelengths of light may alternatively be obtained from a remotelylocated broadband incandescent lamp, with use of wavelength-specificband-pass filtering, or from remotely located LEDs or lasers, withtransmission of the illumination light to the skin surface using opticalfibers. Further, the light that has diffused through the subject's skinmay be conveyed by optical fiber from the subject's skin surface to aremotely located detector. An alternative may be use of an unfilteredbroadband light source for illumination, with the broadband lightconveyed to the skin by optical fiber, and with return of theskin-diffused light by a separate optical fiber to a spectrometer forwavelength-specific detection and analysis. These alternativeapproaches, among others, may be effectively used for research purposes,or when the skin surface is immersed in water or otherwise cannot beaccessed by electrical wiring.

Another aspect of the disclosure are the methods of calibration, datacalculation, and display as these relate to the physiology beingmonitored. Most currently used biometrics are scalar, meaning that theyare calibrated, calculated, and displayed as continuous numeric scales.The recently discovered PI signal, on the other hand, is observed touniquely have a central numeric value region, with differing anddiscernable signal deviation patterns on either side. By convention, themiddle of the central region is disclosed as “PI zero,” with onediscernable deviation pattern going progressively more negative, and theother deviation pattern going progressively more positive in numericalvalue. The calculated PI information is being disclosed as an index, andnot as a means of identifying or measuring the presence or concentrationof specific molecules within the skin. Therefore, the numeric rate ofchange of PI value was initially defined to provide acceptable numericresolution using existing electronic components and software control andcalculation methods. Also, it has been found through experimentalobservation that there is a need to accommodate the naturally widevariation in degree of skin pigmentation, the range of skin tissueopacity to the wavelengths used, and possibly other normal variationsthat must be accommodated to create a practical biometric instrument.

A normalization process is also disclosed whereby the initial PI zerovalue is established and the resolution of the PI value calculation isoptimized. This process starts by step-wise ramping up, under softwarecontrol, the power to the 660+/−10 nm (RED) LED, with the sensor securedon the desired surface of the skin of the user who is at rest, until thedigital count of the sensor signal to the analog-to-digital (A/D)converter results in an output value at about the 80% of the maximum A/Dcount. The RED LED power level is then fixed in control memory. Thepower to the 850+/−10 nm (IR) LED is then step-wise ramped up until it'sdetected A/D count is just less than (i.e. one IR LED power level stepless than) the A/D count produced by the RED LED at its fixed powerlevel; whereupon the IR led power level is fixed in control memory.Alternating signal samples at each of these wavelengths are thenobtained at 1 second intervals and the average difference in A/D countover one minute is calculated. This averaged offset value is then storedin control memory to be used as a fixed bias offset such that when theA/D count value of the IR sample is subtracted from the A/D count valueof the RED sample, less the fixed bias offset, the beginning PI value iszero. Subsequent measurements and calculations continue to use the fixedbias in calculating the PI value as the user, for example, performs anexercise routine.

The disclosed physiologic sensors are configurable to detect, by two-,or multi-wavelength photonic signal variation, an accumulation ofmolecular reaction intermediates of anaerobic (i.e. glycolysis) energyconversion metabolism in skin or other body tissue. The detected signalfrom a sensor placed on the skin or surgically exposed internal organcan also be used as an indicator of excessive tissue oxygen deliveryrate for aerobic (i.e. glycolysis+Krebs Cycle) energy conversionmetabolism; as a surrogate, or direct index, respectively, of theadequacy of the tissue oxygen delivery rate needed to meet, but notexceed the safe limits of, the vital internal organ tissue's need foroxygen to perform energy conversion with minimal injury.

Another aspect of the disclosure is directed to photonic physiologicsensors that are configured to detect, by two-, or multi-wavelengthphotonic signal variation, what is believed to be an accumulation ofmolecular reaction products in the skin resulting from excess highlyreactive oxygen free radical atoms (e.g. O⁻) or molecules (e.g. O₂ ⁻ andOH⁻, H₂O₂, NO, etc., also referred to as reactive oxygen species, orROS) combining, by spontaneous chemical reaction, with tissue andcellular lipid, protein, and DNA molecules in the skin. In some cases,such as with premature infants, current published research isincreasingly emphasizing the need to prevent the accumulation of excessROS in the brain, eyes, and gut. The disclosed PI monitoring method ispresented as a rapidly responsive, non-invasive surrogate index fordetecting the accumulation of such ROS excess in vital organ tissues.

Disclosed are photonic sensors that are non-invasive and minimallyaffected by common sources of mechanical, electronic, electromagnetic,and optical signal noise. Moreover, the disclosed sensors areconfigurable to respond in a timely fashion to detect importantphysiologic changes within the tissue/s being monitored. The disclosedsensors may be used to provide a feedback control signal for automatedregulation of oxygen fraction in the breathing gas to help prevent vitalorgan injury from either tissue hypoxia or hyperoxia during surgicalanesthesia and critical medical care. Additionally, the disclosedsensors can be embodied in a variety of comfortable, wearable formatscompatible with use on adults and children for a wide variety ofoutpatient medical and non-medical applications. Users of such variousembodiments may include, for several needful examples, medical andsurgical patients of all ages and sizes, and at all levels of pathology,and athletes and workers in high risk occupations. In at least someconfigurations and applications, sensors are configurable to alsoprovide an adjunct reflectance pulse oximeter (SpO₂) sensor function,as, for example, for use with newborn infants suffering from lungdisease, where it is also important to monitor arterialhemoglobin/oxygen saturation as an index of lung function. Such aninfant-specific format could be created to be compatible with use in thenewborn intensive care setting and integrated into the electrocardiogram(ECG) contacts placed on the infant's chest and abdomen.

The disclosed sensors are also configurable to prevent emitted lightfrom directly shunting from the light emitter/s to the light detectorwithin the sensor housing. In some configurations, anempirically-derived lateral offset distance is applied between theapertures for the light emitters and detector element. In a fiber opticconfiguration, the optical fibers may be brought to illuminate adjacentregions of the skin surface via separate sheaths and apertures.Applications to surgically-exposed internal organs may, likewise, useoptical fibers, with the illumination and detection apertures located invarious configurations. The optical fibers may also be temporarilyimplanted within solid organs for research, or surgical or medical caremonitoring purposes, with their exposed ends arrayed in variousconfigurations to optimize the photonic signals received.

Yet another aspect of the disclosure is directed to optical physiologicsensors that are configured to detect, by two-, or multi-wavelengthphotonic signal variation, an abnormal skin microcirculatory regulationand/or skin tissue metabolic response to systemically circulatingbacterial endotoxin as an early indicator of the onset of pathologicsepsis-induced inflammatory dysregulation of blood perfusiondistribution; as a surrogate index of impending circulatory compromiseof more vital body tissues.

Another aspect of the disclosure is directed to diffusion opticalphysiologic sensors that are configured to detect, by two-, ormulti-wavelength photonic signal variation, the skin microcirculatoryand/or skin tissue metabolic response to insufficient systemiccirculatory volume loading, such as due to, for example, general bodydehydration, blood loss from trauma, or blood loss during surgicaloperation; as a surrogate index for perfusion of vital organ tissues,where normal life-preserving autonomic nervous system reflex responsesattempt to sustain the perfusion of vital organs at the expense ofperfusion of the skin.

Also disclosed are physiologic sensors that are configured becontinuously wearable in order to detect gradual exacerbation ofchronic, progressive ailments including, for example, heart failureand/or chronic obstructive pulmonary disease (COPD), such that impendingcrises can be detected early enough to enable cost-effective outpatientcare, instead of gradually progressing unnoticed until hospitaladmission or re-admission becomes a crisis imperative.

A physiologic sensor and/or blood oximeter sensor is disclosed using a“blue enhanced” NIR PIN photodiode, or equivalent alternative, having anupward ramping spectral sensitivity between about 600 nm and about 950nm. Additionally, such a sensor package can include a metal, orotherwise opaque to visible through near-infrared (NIR) wavelengths,light shield between the light emitters and the photodetector, to reducelight shunting within the sensor package. Additionally, such a sensormay be configured with a 5 mm to 9 mm lateral separation between emitterand detector optically clear compound-potted apertures. In someconfigurations, the sensor may be designed for application to certainskin surfaces, such as, but not limited to, the chest or arm of adults,or the chest, abdomen, or extremities of infant patients, and forapplication to internal organ surfaces or temporary implantation withinsolid organ tissues during and/or following surgical operation.

Additional aspects of the disclosure include physiologic sensors thatare configurable to detect, by two-, or multi-wavelength photonic signalvariation, the degree of physiologic loading due to physical exertion.Physical exertion can be roughly segmented into two categories: (1)anaerobic, which can provide rapid onset, high force body motions overshort periods of time, such as weight lifting and sprinting, and (2)aerobic, which can support much longer duration, but relatively lowerintensity continuous body motions, such as marathon running. Athletestraining for, and performing in one or the other type of activity havebeen found to benefit from narrowly defined, performance-specific typesof training and conditioning exercise sessions. Examples of this includeanaerobic-type performance needing multiple brief, high force generationcycles, with full recovery between, which has been found to stimulateup-regulation of enzyme systems needed for generation of adenosinetriphosphate (ATP) by glycolysis. On the other hand, long distancerunners have been found to benefit most from prolonged, fully aerobicexercise sessions, avoiding even brief periods of anaerobic metabolism,to up-regulate their enzyme systems needed for converting fats for usein aerobic energy conversion. Until the discovery of the PI signal,there has not been a convenient, objective, wearable method of sensingwhen the athlete is using primarily anaerobic, vs. aerobic energyconversion chemistry during exercise.

Another embodiment may integrate both PI and reflectance SpO₂ sensorfunctions, where these two biometrics each provide highly relevant,related, and complementary information in many useful applications. Inthis integrated format, such as for use on the chest and abdomen of apremature infant, the SpO₂ monitor function primarily provides anindication of the adequacy of the lungs to obtain oxygen, and thecomputed PI value provides an index of skin tissue oxygenation, as asurrogate for oxygen delivery by the blood to the brain and other vitalinternal organs. Existing SpO₂ monitors are well known to be easilycompromised by sensor motion-induced optical signal artifacts thattemporarily prevent accurate computation of the SpO₂ value, which, inturn, may trigger false alarms and, alternatively, may result in failureto initiate an alarm during real alarm conditions. On the other hand,the PI sensor is more quickly responsive to changes in oxygen deliveryat the skin tissue level, and is inherently immune to sensormotion-induced signal artifact due to the tandem pattern of thevariations that occur in the raw signal values with sensor motion. Thus,the PI value can be safely and effectively relied upon to provide abackup index to eliminate false SpO₂ alarms and to avoid missing realSpO₂ alarm conditions accompanied by sensor motion.

The disclosed sensors are also configurable to apply optimal wavelengthsof emitted light and to select an optimum spectral sensitivity responseprofile of the light detector. Additionally, the disclosed sensors areconfigurable to have computer control, computer data processing,computer data storage, and wired or wireless data communications inaccordance with existing capabilities, and expected future advances, inthese areas of technology.

The disclosed sensors are configurable to be automatically initializedto accommodate natural variations in skin pigmentation, thickness, andspectral optical density at the two or more wavelengths of illuminationlight.

The disclosed sensors are also configurable to provide feedback signalsto guide breathing gas blending of oxygen fraction, typically startingtherapy at an oxygen fraction below atmospheric by blending oxygen withnitrogen gas, to avoid initially providing excessive oxygen to vitalorgan tissues above the tissue's need and tolerance level. By this newmeans, premature infants and patients being resuscitated from hypoxemiaand/or ischemia stress, may be protected from inadvertent injury fromexcess oxygen delivery to vital organ tissues. Further, when specificpatterns of change in the PI signal indicate the need, the disclosedsensors can be used to automatically command incremental increases inthe breathing gas oxygen fraction in response to the oxygen need andtolerance of the skin, as a surrogate of internal vital organs, innon-invasive applications. Finally, with surface application to internalorgans exposed surgically, or with fiber optic light guides inserteddirectly into solid organs, the PI signal is disclosed as a previouslyunavailable means of direct, real-time indication of vital organ tissueneed for, and tolerance of, delivered oxygen via blood perfusion.

An aspect of the disclosure is directed to physiologic index sensors.Suitable sensors comprise: a first means for emitting a first wavelengthwherein the first means for emitting the first wavelength isconfigurable to emit a first target wavelength of from 650 nm to 670 nm;a second means for emitting a second wavelength wherein the second meansfor emitting the second wavelength is configurable to emit a secondtarget wavelength of from 840 nm to 860 nm; a detection means opticallyisolated from the first means for emitting the first wavelength and thesecond means for emitting the second wavelength; and a processor meansconfigured to receive an input from the detection means. In someconfigurations, the physiologic index sensor further comprises a datatransmitter means. Additionally, the physiologic index sensors can beconfigurable to determine one or more of an index of oxygen delivery andaerobic energy conversion. A housing means can be provided having afirst aperture and a second aperture. Additional apertures can beprovided without departing from the scope of the disclosure.Additionally, one or more of the apertures can be filled with anoptically clear material. A securer means can be provided which isconfigured to secure the physiologic index sensor to a user, such as atan arm or a chest. One or more electrically conductive skin contactadhesive means can be provided. In some configurations, at least one ofthe first means for emitting the first wavelength and the second meansfor emitting the second wavelength is connected to a physiologic indexsensor housing via a cable. Additionally, at least one of the firstmeans for emitting the first wavelength and the second means foremitting the second wavelength is an unfiltered broadband light source,using optical fiber cables for light conveyance to and from the skin,and the detection means is a spectrometer, with selected wavelengthintensity values obtained by the spectrometer used to compute thephysiologic index.

Another aspect of the disclosure is directed to physiologic indexsensors. Sensors can comprise: a first emitter for emitting a firstwavelength wherein the first emitter for emitting the first wavelengthis configurable to emit a first target wavelength of from 650 nm to 670nm; a second emitter for emitting a second wavelength wherein the secondemitter for emitting the second wavelength is configurable to emit asecond target wavelength of from 840 nm to 860 nm; a detector opticallyisolated from the first emitter and the second emitter; and a processorconfigured to receive an input from the detector. The physiologic indexsensors can further comprise a data transmitter. Additionally, thephysiologic index sensors can be configurable to determine one or moreof an index of oxygen delivery and aerobic energy conversion. A housingcan be provided having two or more apertures. One or more apertures canbe filled with an optically clear material. A securer can be configuredto secure the physiologic index sensor to a user such as at an arm or achest. One or more electrically conductive skin contact adhesive padscan also be provided. Additionally, at least one of the first emitterfor emitting the first wavelength and the second emitter for emittingthe second wavelength is connected to a physiologic index sensor housingvia a cable. In some configurations at least one of the first emitterfor emitting the first wavelength and the second emitter for emittingthe second wavelength is an unfiltered broadband light source, with twoor more wavelength intensity values being selected by a spectrometer tobe used to compute a physiologic index value.

Still another aspect of the disclosure is directed to physiologic indexsensors comprising: a housing adapted to engage a chest or an arm of auser wherein the housing has a first aperture and a second aperture; afirst emitter wherein the first emitter is configurable to emit a firstwavelength of from 650 nm to 670 nm through the first aperture; a secondemitter wherein the second emitter is configurable to emit a secondwavelength is configurable to emit a second target wavelength of from840 nm to 860 nm; a detector disposed within the housing wherein thedetector is optically isolated in the housing from the first emitter andthe second emitter and adjacent the second aperture; and a processorconfigured to receive an input from the detector. The physiologic indexsensors can further comprise a data transmitter. Additionally, thephysiologic index sensor is configurable to determine one or more of anindex of oxygen delivery and aerobic energy conversion. Two or moreapertures can be provided which can be filled with an optically clearmaterial. A securer can be provided which is configured to secure thephysiologic index sensor to a user, such as to the arm or the chest ofthe user. In some configurations, at least one of the first emitter foremitting the first wavelength and the second emitter for emitting thesecond wavelength is connected to a physiologic index sensor housing viaa cable. Additionally, at least one of the first emitter for emittingthe first wavelength and the second emitter for emitting the secondwavelength is an unfiltered broadband light source, with two or morewavelength intensity values being selected by a spectrometer to be usedto compute a physiologic index value.

Yet another aspect of the disclosure is directed to methods of detectinga biological parameter. Suitable methods comprise: placing a physiologicindex sensor in contact with an arm or a chest of a patient wherein thephysiologic index sensor further comprises, a first emitter for emittinga first wavelength wherein the first emitter for emitting the firstwavelength is configurable to emit a first target wavelength of from 650nm to 670 nm, a second emitter for emitting a second wavelength whereinthe second emitter for emitting the second wavelength is configurable toemit a second target wavelength of from 840 nm to 860 nm, a detectoroptically isolated from the first emitter and the second emitter, and aprocessor configured to receive an input from the detector; powering thephysiologic index sensor with a power supply; emitting a light in afirst wavelength and emitting a light in a second wavelength; detectinga diffused light through a tissue; and analyzing the detected signalproduced by the diffused light. Additional steps can include one or moreof the step of: determining an index of oxygen delivery for the patient;transmitting data from the physiologic index sensor to a second device;and detecting an excess oxygen level at a tissue.

Another aspect of the disclosure is directed to a communication system,comprising: a physiologic index sensor in contact with an arm or a chestof a patient wherein the physiologic index sensor further comprises, afirst emitter for emitting a first wavelength wherein the first emitterfor emitting the first wavelength is configurable to emit a first targetwavelength of from 650 nm to 670 nm, a second emitter for emitting asecond wavelength wherein the second emitter for emitting the secondwavelength is configurable to emit a second target wavelength of from840 nm to 860 nm, a detector optically isolated from the first emitterand the second emitter, and a processor configured to receive an inputfrom the detector; a power supply in communication with the physiologicindex sensor to power the physiologic index sensor; a server computersystem; a measurement module on the server computer system forpermitting a transmission of a measurement from the physiologic indexsensor over a network; and at least one of an API engine connected to atleast one of the physiologic index sensor to create a message about themeasurement and transmit the message over an API integrated network to arecipient having a predetermined recipient user name, an SMS engineconnected to at least one of a system for detecting physiologicalparameters and the physiologic index sensor to create an SMS messageabout the measurement and transmit the SMS message over the network to arecipient device having a predetermined measurement recipient telephonenumber, or an email engine connected to at least one of the physiologicindex sensor to create an email message about the measurement andtransmit the email message over the network to a recipient email havinga predetermined recipient email address. Additionally, a storing modulecan be provided on the server computer system for storing themeasurement in a physiologic index sensor server database. In someconfigurations, the physiologic index sensor is connectable to theserver computer system over at least one of a mobile phone network or anInternet network, and a browser on a measurement recipient electronicdevice is used to retrieve an interface on the server computer system.Additionally, an interface can be provided on the server computersystem, the interface being retrievable by an application on a mobiledevice. The server computer system can be connectable over a cellularphone network to receive a response from a measurement recipient mobiledevice. A downloadable application can be provided which resides on ameasurement recipient mobile device, the downloadable applicationtransmitting a response and a measurement recipient phone number ID overa cellular phone network to the server computer system, the servercomputer system utilizing the measurement recipient phone number ID toassociate the response with an SMS measurement.

Still another aspect of the disclosure is directed to a method ofobtaining a physiologic index comprising: deploying a physiologic indexsensor having a first emitter for emitting a first wavelength whereinthe first emitter for emitting the first wavelength is configurable toemit a first target wavelength of from 650 nm to 670 nm, a secondemitter for emitting a second wavelength wherein the second emitter foremitting the second wavelength is configurable to emit a second targetwavelength of from 840 nm to 860 nm, a detector optically isolated fromthe first emitter and the second emitter, and a processor configured toreceive an input from the detector, powering the physiologic indexsensor with a power supply; adjusting a first target wavelength lightsource power level until a resulting signal intensity is about 80% of asensor system A/D converter maximum count limit; recording and lockingthe first target wavelength light source power level in a controlmemory; adjusting a second target wavelength light source power leveluntil a resulting signal intensity is less than the signal intensityproduced by the first target wavelength light source; recording andlocking the second target wavelength light source power level in thecontrol memory; using the respective locked first and second targetwavelength light source power levels to sample a spectral opticaldensity at a sensor site once per second at the first and second targetwavelengths; computing an average difference from the first targetwavelength signal intensity minus the second target wavelength signalintensity; and recording and locking the average difference in thecontrol memory. In some configurations, the method includes computing anaverage difference from the first target wavelength signal intensityminus the second target wavelength signal intensity is performed over 1minute. Additionally, an initialization process can be used toaccommodate one or more of a natural or abnormal variation in a skinpigmentation and a natural or abnormal variation in a spectral opticaldensity of the skin tissue. In some methods the methods can includesampling each of the first and second target wavelength signals, minus atime-adjacent, un-illuminated background signal; and subtracting thesecond target wavelength signal intensity value plus the recorded biasoffset value from the first target wavelength signal intensity value toproduce a physiologic index value. Additionally, the sampling andsubtracting steps can be repeated. Displaying and recording thephysiologic index value can be performed in a one, or more second timedbasis. The methods can further comprise: setting a starting oxygenfraction level at 15% oxygen; increasing the oxygen fraction by 1%;monitoring the physiologic index for 15 seconds for a change in oxygenfraction; if the second target wavelength signal intensity value doesnot decrease, and the first target wavelength signal intensity increasesin response to the 1% increase in oxygen fraction generating a feedbackcontrol command to increase the breathing gas oxygen fraction by 1%. Themethod can further comprise repeating the monitoring and responsecommand cycle by at least one of: if the second target wavelength signalintensity decreases, and the first target wavelength signal intensitydoes not increase in response to a 1% increase in oxygen fraction in thebreathing gas, decrease the breathing gas fraction by 1% and monitor thephysiologic index for one minute; if the first target wavelength signalintensity decreases in response to the 1% decrease in oxygen fraction inthe breathing gas increase the breathing gas oxygen fraction by 1%; andif the second target wavelength signal intensity does not decrease, andthe first target wavelength signal intensity does not increase inresponse to a 1% increase in the oxygen fraction of the breathing gas,the subject's physiologic index “zero” condition has been reached,resulting in a one-minute averaging of the offset of once-per-secondsamples of the first target wavelength signal intensity minus the secondtarget wavelength signal intensity, resulting in recording and locking anew bias offset value in a control menu and indicating that aphysiologic index “zero” has been reset.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in thisspecification are herein incorporated by reference to the same extent asif each individual publication, patent, or patent application wasspecifically and individually indicated to be incorporated by reference.References include, for example:

-   U.S. Pat. No. 5,830,137 A to Scharf issued Nov. 3, 1998 for “Green    Light Pulse Oximeter;”-   U.S. Pat. No. 6,801,799 B2 to Mendelson, issued Oct. 5, 2004, for    “Pulse Oximeter and Method of Operation;”-   U.S. Pat. No. 7,691,067 B2 to Westbrook, issued Apr. 6, 2010, for    “Method for Measuring Central Venous Pressure or Respiratory    Effort;”-   U.S. Pat. No. 7,738,935 B1 to Turcott, issued Jun. 15, 2010, for    “Methods and Devices for Reduction of Motion-Induced Noise in Pulse    Oximetry;”-   U.S. Pat. No. 8,073,516 B2 to Scharf issued Dec. 6, 2011, for    “Separating Motion from Cardiac Signals Using Second Order    Derivative of the Photo-Plethysmogram and Fast Fourier Transforms;”-   U.S. Pat. No. 8,133,176 B2 to Porges, issued Mar. 13, 2012, for    “Method and Circuit for Indicating Quality and Accuracy of    Physiological Measurements;”-   U.S. Pat. No. 8,346,327 B2 to Campbell, issued Jan. 1, 2013, for    “Method for Identification of Sensor Site by Local Skin Spectrum    Data;”-   US 2006/0009685 A1 to Finarov et al. published Jan. 12, 2006 for    “Device and Method for Non-Invasive Optical Measurements;”-   US 2008/0208009 A1 to Shklarski published Aug. 29, 2008 for    “Wearable Device, System and Method for Measuring Vital Parameters;”-   US 2008/0081966 A1 to Debreczeny published Apr. 3, 2008 for    “Symmetric LED Array for Pulse Oximetry;”-   US 2010/0324390 A1 to McLaughlin, published Dec. 23, 2010, for    “Measurement of Oxygen Saturation of Blood Haemoglobin,”-   US 2011/0054336 A1 to Jornod published Mar. 3, 2011 for “Method and    Device for Measuring the Pulse by Means of Light Waves with Two    Wavelengths;-   US 2013/0317331 A1 to Bechtel, published Nov. 28, 2013, for “Monte    Carlo and Iterative Methods for Determination of Tissue Oxygen    Saturation;”-   US 2015/0057511 A1 to Basu, published Feb. 26, 2015, for “Sensor and    Method for Continuous Health Monitoring;”-   US 2015/0011854 A1 to Frix, published Jan. 8, 2015, for “Continuous    Transdermal Monitoring System and Method;”-   US 2013/0303921 A1 to Chu, published Nov. 14, 2013, for “System and    Method for Measurement of Physiological Data with Light Modulation;”-   US 2014/0275888 A1 to Wegerich published Sep. 18, 2014 for “Wearable    Wireless Multisensor Health Monitor with Heat Photoplethysmograph;”-   WO 2015/168235 A1 to Hatch published Nov. 5, 2015, for    “Physiological Sensors, Systems, Kits and Methods Therefor;”-   “Facts About Retinopathy of Prematurity,” National Eye Institute,    https://nei.nih.gov/health/rop/rop;-   Azizbeigi, K., et. al., “Antioxidant enzymes and oxidative stress    adaptation to exercise training: Comparison of endurance,    resistance, and concurrent training in untrained males.” J. Exerc.    Sci. Fit., 12:1-6 (2014);-   Balk N, et. al., “Cerebral haemorrhage in preterm neonates: does    cerebral regional oxygen saturation during the immediate transition    matter?,” Arch Dis Child Fetal Neonatal Ed 100(5):F422-7, PMID:    26066762 (September 2015);-   Balu M, et. al., “In vivo multiphoton NADH fluorescence reveals    depth-dependent keratinocyte metabolism in human skin,” Biophysical    Journal 104(1):258-67, PMID: 23332078 (Jan. 8, 2013);-   Bangsbo, J. et. al. “Training and Testing the Elite Athlete,” J.    Exerc. Sci. Fit. 4(1) (2006);-   Benini, R., et. al., “Influence of sex on cytokiones, heat shock    protein and oxidative stress markers in response to an acute total    body resistance exercise protocol.” J. Exerc. Sci. Fit. 13: 1-7    (2015);-   Celik H, et. al., “Serum prohepcidin levels in premature newborns    with oxygen radical diseases,” J. Matern. Fetal Neonatal Med.    28(18):2228-33, PMID: 25363011 (2015);-   Coquart, J., et. al., “Effects of a training program at the    crossover point on the cluster of metabolic abnormalities and    cardiovascular risk factors.” J. Exerc. Sci. Fit., 12: 73-79 (2014);-   Dawson J A, et. al., “Defining the reference range for oxygen    saturation for infants after birth,” Pediatrics 125:e1340-e1347,    PMID: 20439604 (2010); Dey, S., et. al., “Compartment-specific    control of reactive oxygen species scavengng by antioxidant pathway    enzymes,” J. Biol. Chem. PMID: 27048652 (Apr. 5, 2016);-   Dice, et. al., “Patent ductus arteriosus: an overview.” J. Pediatr    Pharmacol Ther. 12(3):138-46. PMID: 23055849 (July 2007);-   Duun, et al. “A Ring Shaped Photodiode Designed for Use in a    Reflectance Pulse Oximetry Sensor in Wireless Health Monitoring    Applications,” IEEE Sensors Journal, Vol. 10(2) (February 2010);-   Eluamai, A., et. al., “Effect of aerobic exercise on mitochondrial    DNA and aging.” J. Exerc. Sci. Fit. 11: 1-5, (2013);-   Fontaine et al. “Reflectance-Based Pulse Oximeter for the Chest and    Wrist” Worcester Polytechnic Institute (2013);-   Gaynor, P., et. al., “A hard/heavy intensity is too much: The    physiological, affective, and motivational effects (immediately and    6 months post-training) of unsupervised perceptually regulated    training.” J. Exerc. Sci. Fit. 13: 123-130, (2015);-   Haahr, “A Novel Photodiode for Reflectance Pulse Oximetry in    Low-Power Applications,” Proceedings of the 29th Annual    International Conference of the IEEE EMBS (August 2007);-   Hafner, et. al., “Hyperoxia in intensive care, emergency, and    peri-operative medicine: Dr. Jekyll or Mr. Hyde? A 2015 update,” Ann    Intensive Care 5(1):42, PMID: 26585328 (December 2015);-   Harms, F A, et. al., “Cutaneous mitochondrial respirometry:    non-invasive monitoring of mitochondrial function,” J. Clin. Monit.    Comput. 29:509-519, PMID: 25388510 (2015);-   Horiuchi, M., et. al., “Comparisons of energy cost and economical    walking speed at various gradients in healthy, active younger and    older adults.” J. Exerc. Sci. Fit. 13: 79-85, (2015);-   Jianxiong, W. et. al., “Exercise training at the maximal fat    oxidation intensity improved health-related physical fitness in    overweight middle-aged women.”, J. Exerc. Sci. Fit., 13:111-116,    (2015);-   Lakshminrusimha, S, et. al., “Oxygen targeting in preterm infants: a    physiologic interpretation,” J. Perinatol. 35(1):8-15, PMID:    25357098 (January 2015);-   Lawler, J M., et. al., “Mitochondria in the middle: Exercise    preconditioning protection of striated muscle.” J. Physiol., PMID:    27060608 (Apr. 6, 2016);-   Maia, M., et. al., “Maximal repetition performance, rating of    perceived exertion, and muscle fatigue during paired set training    performed with different rest intervals.” J. Exerc. Sci. Fit.,    13:104-110, (2015);-   Manja V, et. al., “Oxygen saturation target range for extremely    preterm infants: a systematic review and meta-analysis,” JAMA    Pediatr. 169(4):332-40, PMID: 25664703 (April 2015); Marseglia L,    et. al., “Oxidative stress-mediated damage in newborns with    necrotizing enterocolitis: a possible role of melatonin,” PMID:    25738791 (August 2015);-   Miller, et. al., “Antenatal antioxidant treatment with melatonin to    decrease newborn neurodevelopmental deficits and brain injury caused    by fetal growth restriction,” J. Pineal Res. 56(3): 283-94. PMID:    24456220 (April 2014);-   Ovadia-Blechman Z, et. al., “Noninvasive monitoring of peripheral    microcirculatory hemodynamics under varying degrees of hypoxia,”    Respir. Physiol. Neurobiol. 22(216):23-27, PMID: 26006296 (May    2015);-   Perrone S, et. al., “The role of oxidative stress on necrotizing    enterocolitis in very low birth weight infants,” Curr. Pediatr.    Rev.10(3):202-7, PMID: 25088341 (2014);-   Pujary, “Investigation of Photodetector Optimization in Reducing    Power Consumption by a Noninvasive Pulse Oximeter Sensor,” Worcester    Polytechnic Institute (2004);-   Rei M, et. al., “Neurological damage arising from intrapartum    hypoxia/acidosis,” Best Pract Res. Clin. Obstet Gynaecol; Best    Pract. Res. Clin. Obstet. Gynaecol. PMID: 26148854 (Jun. 21, 2015);-   Stanula, A., et. al., “Calculating lactate anaerobic thresholds in    sports involving different endurance preparation.” J. Exerc. Sci.    Fit., 11: 12-18, (2013);-   Suffoletto B, et. al., “Near-infrared spectroscopy in post-cardiac    arrest patients undergoing therapeutic hypothermia,” J.    Resuscitation 83(8):986-90, PMID: 22521725 (August 2012);-   Tokuhisa T, et. al., “Outcome of infants with hypoxic ischemic    encephalopathy treated with brain hypothermia,” J. Obstet. Gynaecol.    Res. 41(2):229-37, PMID: 25346401 (February 2015);-   Torres-Cuevas, et. al., “Oxygen supplementation to stabilize preterm    infants in the fetal to neonatal transition: no satisfactory    answer,” Front Pediatr. 4:29, PMID: 2714850 (April 2016);-   Verhagen E, et. al., “Cerebral oxygenation in preterm infants with    germinal matrix-intraventricular hemorrhages,” Stroke 41(12):2901-7,    PMID: 20966409 (December 2010);-   Yli M B, et. al., “Pathophysiology of foetal oxygenation and cell    damage during labour,” Best Pract Res. Clin. Obstet Gynaecol;    30:9-21, PMID: 26211833 (Jun. 21, 2015); and-   Zhong-Wie Z, et. a., “Mitochondrion-permeable antioxidants to treat    ROS-burst-mediated acute diseases,” Oxid. Med. Cell. Longev.    2016:6859523, PMID: 26649144 (2016).

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity inthe appended claims. A better understanding of the features andadvantages of the present invention will be obtained by reference to thefollowing detailed description that sets forth illustrative embodiments,in which the principles of the invention are utilized, and theaccompanying drawings of which:

FIG. 1A illustrates the sensor viewed from the skin contact side;

FIG. 1B shows the sensor with the aperture plate removed;

FIG. 1C is a cross-section of the sensor;

FIGS. 2A-B illustrate data recordings of the derived Physiologic Index(PI) using 660 nm and 810 nm during a hypoxia challenge test where thesubject is breathing nitrogen-diluted air;

FIG. 3A illustrates placement locations for the disclosed sensor;

FIG. 3B illustrates differences between reflectance pulse oximetry(SpO₂) and the sensor on a skin surface;

FIG. 4 illustrates an alternative embodiment having 2 sensors;

FIG. 5 illustrates an embodiment of the sensor using a lamp source and aspectrometer;

FIGS. 6A-C illustrate features of a skin contacting portion of a deviceconfigurable to place the ends of two optical fibers in optical contactwith the skin;

FIGS. 7A-B are line graphs of data recorded, and of a derived PI, using660 nm and 850 nm light during a hypoxia challenge test wherein thesubject is breathing nitrogen-diluted air;

FIGS. 8A-B are line graphs of data recorded, and of a derived PI using660 nm and 850 nm light during a hyperoxia challenge test where thesubject is breathing pure oxygen;

FIGS. 9A-B are line graphs of data recorded, using a heart rate monitor,a Moxy Monitor (SpO₂ in a large muscle vs. fingertip), and a PI sensorusing 660 nm and 850 nm light during an exercise challenge test;

FIGS. 10A-B are line graphs of data recorded, and of a derived PI using660 nm and 850 nm LED light, in parallel with a QTH lamp light sourceand a spectrometer during a hyperoxia challenge test; breathing pureoxygen;

FIG. 11 is a line graph of data recorded using a QTH lamp light sourceand a spectrometer to obtain PI values during an exercise challengetest;

FIG. 12 illustrates the interrelationship of the three PI data phases;

FIG. 13 outlines the initialization process of the PI sensor software;and

FIG. 14 outlines a proposed algorithm that could be used to regulate thebreathing oxygen fraction delivered to monitored subjects.

DETAILED DESCRIPTION

The present disclosure provides an optically efficient tissue lightdiffusion/absorption mode sensor for monitoring spectral optical densityvariations that have been found to be associated with alterations intissue metabolic chemistry. These sensors can be used on subjects of allages and sizes to determine a Physiology Index (PI). As will beappreciated by those skilled in the art, the disclosed sensors are notblood oximeter devices, but rather, sensors configured to detectspectral photonic responses relating to, for example, mammalian skintissue metabolic chemistry as two or more wavelengths of light passthrough the tissue at the sensor site. Experimental data demonstratesthat these sensor responses apparently result from accumulation ofenergy conversion metabolism-related molecules within the skin. Twodistinct phases of response have been detected: (1) when the level ofintracellular oxygen in skin tissue is not sufficient for aerobic energyconversion metabolism (negative PI values) and (2) when there is excessintracellular oxygen leading to potentially damaging, spontaneouschemical reactions between excess ROS and tissue component molecules(positive PI values). In between these two opposing signal responsephases is a ‘normal’ tissue energy conversion metabolism statuscorresponding to fully acclimated aerobic tissue energy conversionmetabolism (i.e. PI zero). Experimental challenge tests have shownstrong circumstantial correlation between the imposed changes, e.g. byeither increasing or decreasing the oxygen fraction of the breathingair, and the corresponding PI sensor signal responses revealing thestatus of skin tissue energy conversion metabolism.

As will be appreciated by those skilled in the art, both transmission(finger-tip) and reflectance (flat surface of the skin) SpO₂ sensorsgenerate a continuous, scalar measurement of the percenthemoglobin-oxygen saturation, which is useful in assessing the gasexchange function in the lungs. However, neither transmission norreflectance SpO₂ can reveal when the illuminated skin tissue is fullyacclimated and experiencing normal aerobic metabolism in real time, orwhen the skin tissue is being provided too little or too much oxygen.

The disclosed sensor design is configurable for convenient placement ona subject's upper arm, held in place with an arm band, or on the chest,held in place with adhesive or a chest strap. These locations reduce thelikelihood of sensor motion-generated artifact. A metallic light barriercan be provided within the sensor housing between the light emitter thephotodetector to prevent shunting of the emitted light within thehousing to the detector. The lateral separation between the lightemitting diode (LED) light emitter aperture and the photodiode sensoraperture can be between 5 mm and 9 mm. In the preferred embodiment, twoLEDs are provided, e.g. with center wavelengths at about 660 nm andabout 850 nm, as the light emitters, and a “blue enhanced” siliconphotodiode as the photodetector.

LED light may be individually and periodically generated at each of thetwo or more wavelengths, to provide the component signal samples, taken,for example, at one second intervals. Each wavelength signal sample, thetotal duration of which may be about 5 milliseconds, may furthercomprise a rapid sequence of multiple, very brief LED illuminations,with very brief intervening periods of no generated light. By thisprocess, the photodiode sensor can detect the net average signal valueat each wavelength; i.e. total averaged illuminated signal, less thecombined effect of the averaged circuit noise and ambient light samples,respectively. Computation of a PI value is achievable by subtracting anet signal value of the IR sample from a time-adjacent net red signalvalue.

In an infant intensive care monitor sensor embodiment, the PI sensorfunctions can be integrated with an adjunct reflectance SpO₂ monitoringfunction. This combination sensor can be further integrated with anadjunct electrocardiogram (ECG) signal detection system using multipleelectrode skin contacts and electronic amplification, and graphicallydisplayed together for clinical evaluation. The R-wave of a detected ECGsignal can also be used to electronically create a timing trigger pulsefor calculating the heart rate and beat-to-beat intervals for displayand further analysis. The initialization and calibration cycle of theinfant monitor system can also include determining the respective timedelays from the R-wave trigger pulse to the following ‘trough’ and‘peak’ in the continuous photoplethysmogram (PPG). Once these timeintervals are determined, subsequent sampling of the IR and RED signalsmay occur only at the timed intervals of the ‘trough’ and ‘peak’ of eachheart cycle. Thus, in the infant intensive care monitor embodiment, boththe PI and the SpO₂ values can be continuously calculated from these twosignal samples per heart cycle.

FIG. 1A illustrates a sensor 100 viewed from a skin contact side. Thesensor 100 is a PI sensor which has a planar surface and a round formfactor. Other shapes can be used without departing from the scope of thedisclosure. A first LED 101 and a second LED 101′ can communicate lightto a subject's skin through a first housing aperture 102. The first LEDand second LED are turned on separately. As will be appreciated by thoseskilled in the art, each LED could have a separate aperture, however, asingle aperture as illustrated can also be used. A silicon photodiode103 is visible through a second housing aperture 104. The housing of thesensor 100 has a skin contact plate 110, and a side wall 112. Aconnecting cable 120 can be provided. Alternatively, the sensor 100 canbe in wireless communication with another device.

FIG. 1B illustrates the sensor 100 with the skin contact aperture plate110 removed to show an embodiment of the optical physiologic sensor. TwoLEDs 101, 101′ are mounted beneath a first housing aperture 102. Thesilicon photodiode 103 is mounted beneath a second housing aperture 104.As illustrated, the first housing aperture 102 has a smaller area thanthe second housing aperture 104. Additionally, an 8 mm center-to-centeroffset can be provided between first housing aperture 102 and secondhousing aperture 104 in the skin contact aperture plate 110. Theaperture plate can be made from any suitable material, including, forexample, metal. An embodiment of the optical medium filling theapertures is optically clear epoxy, such as Epo-Tek P/N 301-2. The viewin FIG. 1B shows the internal optical elements, plus an internal opticalbarrier 105, which is positioned to block internal light transmissionbetween the emitters and the detector. The internal optical barrier 105is configured as an interior wall with a circular shape. However, otherbarrier shapes can be used without departing from the scope of thedisclosure. Additionally, power to operate the sensor can be provided tothe sensor 100 via an internal power supply (such as a battery) or viaan external power supply.

FIG. 1C is a cross-section of the sensor 100 with the LEDs mountedwithin the interior cavity of the sensor.

FIGS. 2A-B illustrate graphical recordings from an initial experimentusing a sensor according to the disclosure. The recording illustratesthat the DC (running average, or non-pulsatile) signal intensitymeasurements, then recorded using 660 nm 201 and 810 nm 202 LED light,consistently and uniquely vary coincidentally with decreasing bloodhemoglobin-oxygen saturation as follows: (1) diffused light signal valueof about 660 nm 201 (RED) light diverges from (2) the diffused lightsignal value of the about 810 nm (IR) light 202; i.e. the red signalintensity value decreases relative to the detected intensity valueresponse of the IR signal with a hypoxic challenge. The disclosed PIvalue is derivable by subtraction of the net IR signal value from thenet red signal value. Thus, during progressive tissue hypoxia, inducedby briefly breathing nitrogen-(N₂) diluted air via a non-rebreathingfacemask, the PI value immediately, e.g. within 5 to 10 seconds,decreases to progressively more negative values; then rapidly returns tothe initially calibrated “PI zero” baseline upon changing the breathinggas back to air.

FIG. 2A is a graph of calculated SpO₂ 200 based on the peak and troughvalues of the raw signal depicted by the graph in FIG. 2B. Of note isthe very erratic SpO₂ trace 204 that was purposely disturbed by motionof the sensor vs. the skin of the subject to assess the effect of sensormotion. The SpO₂ calculation formula and conversion factor used was thesame as was widely known in the medical device industry in January,2000.

FIG. 3A depicts two suitable locations for the sensor on an adultsubject 10. Placement of an arm sensor 310 on the upper arm of thesubject 10 is convenient, comfortable, and leaves the wrists and handsof the subject free. A chest sensor 320 can be located on the chest 12of a subject 10 and offers the possibility of integration with detectionof ECG heart rate by use of skin contact electrode stickers andcorresponding electronic circuitry and software.

FIG. 3B illustrates the anatomy of human skin 30 down to the hypodermis36 next to a diagrammatic representation of the skin adjacent a sensor300. The sensor 300 diffuses light 38 through the epidermis 32 and intothe dermis 34 where it interacts with the various tissue elements andcellular chemical processes primarily above the hypodermis 36.Reflectance SpO₂, by contrast, selectively detects the very subtlepulsatile optical signal variations generated by the blood flowing inthe dermal arterioles 40; using this phenomenon to produce an outputvalue corresponding to the arterial blood hemoglobin oxygen saturation.By comparison, the disclosed sensor detects the non-pulsatile, bulklight that has diffused through the epidermis 32 and dermis 34 from theemitter aperture 302. Variations in the spectral optical density of thistissue space, as detected by the photodiode sensor 303 via the detectoraperture 304 are the basis of the output PI signal, as disclosed herein.

FIG. 4 illustrates an alternative embodiment of a sensor 400 suitablefor use with premature newborn infants. Two sensors 410, 415 are used inthis configuration. In use, a first sensor 415 is placed on the upperanterior right chest of the newborn and the second sensor 410 on thelower left abdomen of the newborn. Integrated with these two sensors410, 415 are other contacts that, collectively, comprise one or more of:a 4-lead ECG, chest sound, and skin temperature measurement system 420,420′, which can connect to a headboard-mounted interface circuit via aconnecting cable 430.

FIG. 5 schematically depicts an embodiment of a sensor system. In orderto investigate the disclosed underlying biometric phenomenon in greaterdetail than is possible using fixed-center wavelength LEDs, a broadbandquartz tungsten halogen (QTH) lamp light source 520 (HL-2000-HP-FHSA,Ocean Optics) is coupled to the skin 12 of a test subject with a fiberoptic cable 510 (Thorlabs). Light that has diffused through the skin 12is received and conveyed by a second fiber optic cable 510′ to aspectrometer 530 (Flame-S-USB, Ocean Optics) for light detection andsignal analysis. LabVIEW (National Instruments) software was used in acomputer 560 to operate the lamp shutter, set the operating parametersof the spectrometer, and select the wavelength intensity values to besampled and analyzed to produce a continuous reading and recording ofthe PI values. Recording with this spectrometer system, in parallel witha LED light-based prototype PI sensor, has produced very similarpatterns of response, confirming, and validating previous and currentobservations, and demonstrating that the basis of the PI signal isclosely associated with reproducible changes in the spectral opticaldensity of the skin.

FIGS. 6A and 6B depicts the skin contact face of the fiber opticinterface components of the spectrometer system in FIG. 5. Two apertures602, 604 can be filled with a clear epoxy to convey light into and fromthe skin, respectively. One of the apertures 602 illuminates the skin,while the other aperture 604 receives the light that has diffusedthrough the skin of the subject.

FIG. 6C is a cut view through the optical axis of one of the apertures,showing a silver-coated mirror 610 (Edmund Optics) in contact with theend of the optical fiber 620. The 90° reflected light is projected, orreceived through the respective housing aperture; spaced 8 mm on center.

FIG. 7A is a recording of a hypoxia challenge test using nitrogen gasdelivered to the test subject via a non-rebreathing facemask. A medicaltransmission pulse oximeter (Masimo Radical 7) recorded the SpO₂ 710 viathe subject's finger-tip during the test. The disclosed LED light-basedPI sensor applied to the subject's upper arm produced the PI values oftrace 720. Of note is the approximately 45 second delay 712 in the SpO₂monitor's response to breathing nitrogen gas. By comparison, the PIsignal value began to change within 10 seconds. The PI signal alsoregistered the return to baseline prior to the response of the SpO₂monitor.

FIG. 7B is a line graph of the raw PI data from which the PI values inFIG. 7A were computed. The 850 nm signal line 734 remains less changedthan the 660 nm signal line 732 throughout. It is their relativemovement that is the basis of the computation of the PI values.Superimposed on both traces are variations 730 associated with thesubject's normal breathing. Since the data samples are taken on timedone-second intervals, the appearance of heart cycle-induced pulsationsis not seen.

FIG. 8A is a recording of a hyperoxia challenge test using medicaloxygen gas delivered to the test subject via a non-rebreathing facemask.As with the hypoxia challenge, the PI values 810 begin to change within10 seconds, but, in this case, remain at an elevated value beyond theduration of the recording. FIG. 8B is the line graph of the raw PI datafrom which the PI values in FIG. 8A were computed. The 850 nm trace 820responds quickly with a strong decreasing trend relative to the moreconstant 660 nm trace 824. Both traces also show breathing-inducedfluctuations 822.

FIG. 9A is a combined recording of an exercise session using a heartrate monitor (Garmin) 910 and a SmO₂ monitor (Moxy) 920, 930. The heartrate is seen to rise in response to three, three-minute episodes ofincreased effort put forth by the test subject. There is also anincreasing trend in the baseline heart rate due to a more graduallyincreasing baseline work load dialed into the exercise bicycle over thecourse of the session. The lower Moxy trace 930 shows the work load ofthe upper leg muscles, presenting this as the combination of arterial,capillary, and venous blood hemoglobin oxygen saturation within themuscle tissue. It is clear that the muscle extracts much of the oxygenduring heavy work periods. The upper Moxy trace 920 shows the work loadof the upper arm muscles, which is somewhat coincident, but lessseverely affected than that of the leg muscles.

FIG. 9B is the simultaneous recording of PI values 940. The initial sixminutes appear to be aerobic, but the onset of the first and secondsprints are clearly detected as a generalized body stress, since the PIsensor was placed on the subject's other upper arm. Of interest is aconsistently observed upward trend 950 in PI baseline as the exercisesession passes the about 20-minute mark. Even though the third sprintproduces a higher heart rate, the PI trend descends only just below thebaseline PI zero, then resumes a strong upward trend despite theexercise being discontinued 960.

FIG. 10A is the PI sensor record of a PI sensor system recording of anextended observation following a brief challenge 1000 with inhaled pureoxygen 1010.

FIG. 10B is the record produced in parallel by the spectrometer system1020. This parallel recording test was performed to investigate how longthe positive PI value persists and clearly shows that 15 minutes is notlong enough to see even the beginnings of a returning-to-baseline trend.Despite a much more apparently “noisy” trace recorded by thespectrometer, the basic features of the PI value trend are seen in bothrecordings, confirming that the PI signal can be consistently obtainedwith at least two different instrument setups.

FIG. 11 is a spectrometer system-acquired exercise PI recording 1110 ofan extended aerobic exercise bicycle session, which was abruptly stoppedto investigate how high the PI value trend would go. This record doesnot show deep negative PI trend peaks as the athlete was asked to stayconsistently at his sustainable work level.

FIG. 12 illustrates the interrelationship of the three PI data phasesthat have been recorded. Typically, a normal, healthy person at resthas, by definition, a “zero” PI. A continuous recording at rest has beenobserved to wander +/−5 points during moderate activity, such asstanding or walking slowly for up to 5 minutes. PI has also beenrecorded during 2 hours of sitting and working with a computer at adesk; the results exhibited that there is a repeating pattern of agradual positive drift of the PI value up to between 20 and 30 after 2hours. This is expected to quickly return to the original baseline withstanding or walking.

Within a few seconds of the onset of physical exertion, the PI valuetrend is typically negative; the downward rate of which is dependentupon the level of exertion. As exertion continues, and especially withintermittent bouts of extreme exertion, the PI data has consistentlyshown a gradual positive PI baseline value trend, which, in somesubjects can rise into the 200 range after 20 to 30 minutes of exercise.There is a further increase in PI values upon suddenly stopping exertionafter 30 minutes of heavy work. A positive trend of PI value up to about40 has also seen with inhalation of oxygen. The positive trend seen atthe end of exertion and after breathing oxygen have not been recordedlong enough (only 15 minutes to date) to indicate the rate of return tothe previous PI Zero level.

FIG. 13 outlines the initialization process of the PI sensor software.Each subject, and each application site on a given subject, is expectedto have differences in skin pigmentation and spectral optical density.These variations need to be accommodated to allow the sensor to centeron the person's true PI zero. The process starts 1310 with increasingthe RED LED power 1320 to a power level that places the resulting rawsignal intensity at about 80% of the sensor A/D 1322 converter countrange. The 80% value optimizes both the resolution of the sensor andaccommodates potential increases in RED signal intensity that have beenrecorded to date. Once the RED LED power level has been determined andrecorded in control memory the RED LED power is locked 1324, and the IRLED power level is similarly adjusted 1326 to just less than the signalintensity value detected with the RED LED at its locked power level1328; and the IR LED power level is recorded and locked in controlmemory 1330.

Finally, prior to running the PI sensor, the average intensity offsetvalue is determined over an initial one-minute period, with RED and IRsamples taken at 1 second intervals 1340. The average signal offset bias(RED intensity minus IR intensity=offset bias) is then calculated 1350and stored in control memory for use in subsequent calculations of thePI values 1360. Also included in all of these intensity samples isdetection and subtraction of the ambient, or background, signalintensity that is a combination of the sensor circuit noise/bias and anyambient light that may be reaching the sensor.

The running process 1370 is enabled once the initialization process hascompleted, typically in a few seconds over one minute. After the run1370 begins, the RED LED and IR LED are sampled at 1 second intervals1372, the red minus IR offset is determined 1374 and a physiologic indexis calculated 1380.

FIG. 14 outlines an exemplar algorithm for use to regulate the breathingoxygen fraction of subjects, such as premature or distressed infants,who are born fully acclimated to the much lower tissue oxygen deliveryrate of fetal life. It is also intended for use with other criticallyill patients being resuscitated from prolonged ischemic or hypoxemicepisodes, such as stroke, near drowning, suffocation, heart attack, orrespiratory or cardiac arrest. It is assumed in all of these instancesthat the entire body of the patient, including the skin, will begin toreceive supportive care at a lower than normal oxygen acclimation level.In the case of newborn infants, this level would be their prior fetalstatus, possibly lowered further by prolonged moderate stress, such asintrauterine growth restriction (IUGR), or by short term severe stressassociated with the delivery. With non-newborns, the lower oxygenacclimation level is a result of natural adaptation reflex,life-sustaining responses by the autonomic nervous and cardiovascularsystems under neural and endocrine control and, possibly, accompanied bydown-regulation of intracellular antioxidant production and/orrecycling.

In an effort to start with a tissue oxygen delivery rate that is lessthan harmful, some value of oxygen fraction less than atmospheric(20.8%) will likely be needed. This starting point will, ultimately, bedetermined empirically and will become a new part of the expertknowledge and judgment required of clinicians serving in this capacity.For illustrative purposes, the oxygen blend algorithm is started at 15%1410 and then temporarily zero the PI 1412. From there, oxygen isincreased in 1% increments 1414 depending upon the response of the PIsensor. Since recordings to date have shown a consistent responsebeginning at 5 seconds, and well established by 15 seconds, a suitableinterval is 15 seconds 1416 which can be used as the iterative intervalfor updating the blend mechanism. Each initial 15 second cycle will testfor the need to further increase the oxygen blend by 1%. This cyclecontinues up to the point where the IR intensity value begins todecrease 1416, signifying the onset of hyperoxia in the skin. At thatpoint, the oxygen blend is reduced by 1% 1430 and the PI value isreviewed after one-minute 1432 to see if there is a need to move back up1%. Thus, the system will tend to cycle +/−1% in oxygen fraction, whilescanning for the need to either decrease or increase to accommodate theneeds of the patient.

As this process plays out, there will come a point where neither the rednor the IR intensity values will change in response to a 1% change inoxygen fraction 1434, signifying that the subject's actual PI zero hasbeen reached. At that point, a one-minute cycle of averaging the REDminus IR offset is performed to acquire a new offset value 1422, 1424,1426; establishing an updated PI zero. This “re-zeroing” process will beindicated by the system display along with the current oxygen blend andthe trend sequence of PI data values up to that point. No assumption ismade as to the maximum level of oxygen fraction that will be needed;only that that fraction not result in a condition of skin tissuehyperoxia, or leave the patient in a state of skin tissue hypoxia.Ultimately, clinicians will need to determine when the proposedalgorithm has established the patient's normal PI Zero.

Operation

When first applied to the skin, the disclosed sensor control runs aninitial auto-ranging protocol. The initial auto-ranging protocoldetermines the signal levels at both wavelengths and then adjusts, inincremental steps of one or more of emitter power and detector amplifiergain, to maximize the resolution of analog-to-digital (A/D) conversion.Optimization is achieved when the two LED power levels and thecorresponding light detector amplifier gain, produces diffused light DCdigitized numerical values approaching, but not exceeding, about 80% ofthe maximum count limit of the A/D converter. This initializationprocess maximizes the resolution of A/D conversion, thus optimizing theaccuracy of the computed PI (all users) and SpO₂ (infants only) valuesfor each patient, helps compensate for differences in skin thickness andpigmentation, and allows a signal overhead range to accommodate theexpected responses.

In the infant intensive care monitor embodiment, the full PPG signal isthen analyzed for timing from the occurrence of a simultaneouslyobtained heart cycle-derived R-wave timing trigger pulse to the ‘trough’and ‘peak’ PPG inflections. Each application site, and each subjectbeing monitored, will likely have a unique time delay between thederived R-wave trigger pulse and the following ‘trough’ and ‘peak’ inthe PPG optical signal. This variability in time intervals is due to theunique length and elasticity of the arterial pulse conduction pathwaybetween the subject's heart and the sensor site. Once the automatedadjustments have been completed, and the ‘trough’ and ‘peak’ sampletiming intervals determined, the LED power levels, the detectoramplifier gain level, and the sampling time intervals are recorded andlocked as customized computation parameters in the control software.Thereafter, the computed oximetry is acquired and displayed, and thenumerical difference between the two DC levels is continuouslycorrelated with the computed oximetry to validate alarm status.

An additional safety feature may be enabled by PI analysis. In the eventthat a valid oximeter ensemble-averaging sample timing trigger cannot beobtained, such as commonly occurs when a monitored infant is crying, thePI value can be sampled on a default-timed basis. Obtaining diffusedlight levels on a clock-timed basis, such as once per second, willprovide fully adequate data for the PI analysis and appropriate alarmgeneration. Further, in situations where heart rate and oximetry valueshave stabilized, as during quiet sleep, the default-timed mode may alsobe used as a significant sensor power conservation option inbattery-supplied instruments.

An unexpected signal response was noted during an induced hypoxiachallenge test of a prototype reflectance pulse oximeter for use on thechest and/or abdomen of newborn infants. Subsequent work has confirmedand refined this initial observation, revealing the potential for highlyrelevant new applications both in medical care and in the study of humanphysiology. The following explanations apply current knowledge ofbiochemistry and photonics as these disciplines apply to the study ofhuman physiology and pathology. The methods, observations, and proposedexplanations will, hopefully, be familiar and reasonable to students ofundergraduate science and medical school, and who have, subsequently,observed and interacted with human physiology in health and disease.

Two main phenomena appear to be at play. First, skin tissue energymetabolism appears to be the main source of the variation in thephotonic signals used to calculate PI. Factors likely causing variationsin this metabolic chemistry, which apparently cause the resultingphotonic responses, relate directly to the oxygen content of the blooddelivered to the skin. This blood oxygen content is currently routinelymonitored by pulse oximetry (SpO₂), and can be altered by breathingeither nitrogen-diluted air, to reduce the SpO₂, or by breathing pureoxygen to exceed the blood oxygen saturation produced by breathing air;and observing the displayed data.

The second phenomenon appears to be independent of arterial blood oxygencontent and relates to the autonomic nervous system's regulation ofblood perfusion to skin tissue, both as a result of normal adaptation tostress, such as physical exercise and work, and pathologic, due todisease or injury-related processes. This blood perfusion regulation bythe nervous system affects the process of energy conversion metabolismat the intracellular level in the skin. This influence is uniquelydetected by the sensor due to the apparent accumulation of differentmolecules depending on whether insufficient oxygen (i.e. skin tissuehypoxia), or excess oxygen (i.e. skin tissue hyperoxia) is present.

Several areas of potentially significant clinical value of this new PIdata relate to pathologic conditions known to decrease blood perfusionof the skin at the onset of the pathologic deterioration process. Suchconditions as heart failure, resulting in decreased blood pumpingcapacity, and low circulating blood volume, such as due to blood lossfrom trauma or during surgery, trigger the autonomic nervous system torestrict blood perfusion of the skin as a life-protective reflexresponse. This reflex helps to maintain systemic blood pressure andconserves blood flow to preferentially serve the needs of more vitalorgans, such as the brain and heart. Likely the earliest sign of theonset of blood borne infection, or sepsis, is decrease in bloodperfusion to the skin; again as a reflex response to maintain systemicblood pressure as the combination of bacterial toxins in the blood andthe resulting immune system response causes relaxation of major bloodvessels and a drop in blood pressure. Finally, there are several chronichealth conditions, including chronic obstructive pulmonary disease(COPD), which tend to deteriorate at such a gradual rate that thepatient may fail to discern the advancing stress and delay obtainingneeded help until only heroic effort may suffice to preserve life andrecover health. All of these conditions need a highly sensitive,conveniently wearable sensor that indicates the earliest pathologicchanges, in order to signal for the initiation of needed interventionbefore the condition becomes dire; thus, improving quality of life andreducing cost and complexity of health care. SpO₂ monitoring technologyis not currently “wearable” or convenient and does not adequately detectthe skin perfusion reflex response seen early in sepsis and low bloodvolume, and early enough to be useful in detecting exacerbation of heartfailure and COPD.

SpO₂ monitoring also does not detect potentially damaging excess oxygenat the tissue level, where it is toxic. Breathing gas with elevatedpartial pressure of oxygen can result in oxygen toxicity in the centralnervous system, resulting in seizures. Occupations, recreationalpursuits, and medical therapy where this may inadvertently occur includeastronauts, high altitude pilots, SCUBA divers, and patients undergoinghyperbaric oxygen therapy.

Pathologies potentially caused by, or exacerbated by insufficient orexcessive tissue oxygen are also a major concern with premature infantsborn earlier than about 30 weeks' gestation. Injuries include: retinaldetachment and resulting impaired vision and even total blindness, brainhemorrhage, intestinal necrosis and perforation, cerebral palsy, and,most commonly, failure of the ductus arteriosus to close in a timely andcomplete fashion, resulting in an additional assortment of complicationsand life risks. Before birth, fetal blood oxygen saturation, and theresulting tissue oxygen level, are consistently very low compared tothat of healthy full-term newborn infants, children, and adults. Due tothe high efficiency of oxygen transport by fetal hemoglobin, fetusesactually thrive at this low tissue oxygen level and, unless they areborn prematurely, continue to grow and develop normally and are atminimal risk of insufficient oxygen delivery-related injury. The currentpractice of intensive care is to regulate breathing oxygen blendaccording to the blood hemoglobin saturation, as indicated by blood gassampling and SpO₂ monitoring, which cannot indicate whether the tissueoxygen delivery is less than, or more than, the tissue need. Thus, withblood oxygen monitoring only, potentially injuriously high (i.e. higherthan fetal) tissue oxygen levels cannot be detected, and, thus, arecurrently not sufficiently avoidable. Current newborn resuscitationprotocols using immediate administration of lung surfactant andappropriate ventilator treatment of premature lung disease have actuallyincreased the risk of excessive tissue oxygen delivery during theinfant's early transition from fetal placenta to breathing. With rapidlynormalized lung function, even limiting the breathing gas oxygen levelto atmospheric level (20.8%), either with assisted ventilation orspontaneous breathing, may still present an unacceptably high risk ofvital tissue injury due to excess tissue oxygen delivery, compared tothe relatively very low tissue oxygen delivery during fetal life. Thus,there is a combined need for accurate, continuous monitoring of theadequacy of tissue oxygen delivery, coupled withautomatically-regulated, initially lower-than-atmospheric fraction ofoxygen in the breathing gas for the resuscitation and early managementof these very vulnerable infants as they make their transition fromfetal to air-breathing life. Continuously knowing the skin tissue-leveloxygen metabolic status relative to skin tissue metabolic need foroxygen, as a surrogate index for vital organs, has long been arecognized and critical, but unmet, need of premature infant healthcare. The PI sensor described herein offers a potentially viable sourceof this critical information. Applied to the skin of the prematureinfant immediately following birth, the PI sensor's “find PI zero”algorithm can be used to guide the automated regulation of theoxygen/nitrogen blend of the breathing gas mixture, beginning at aless-than atmospheric oxygen fraction, such as at about 15%. Then,periodic, small step increases in the breathing gas oxygen fraction canbe made until PI zero is encountered, whereupon the breathing gas oxygenfraction can be continuously and automatically adjusted to maintain skintissue oxygen delivery to maintain a near-zero PI value, as a surrogateof oxygen delivery to vital organs. Thus, each individual prematureinfant patient can be objectively managed on a unique, automatedtimeline of adaptation toward breathing atmospheric air, or higheroxygen fraction if needed, then weaned to atmospheric oxygen levels asthe lungs mature and heal. The ultimate goal is to reduce the incidenceof the devastating injuries that can be caused by either inadequate orexcess oxygen delivery to the extremely fragile and immature brain, gutand vascular tissues of these infants.

The systems and methods according to aspects of the disclosed subjectmatter may utilize a variety of computer and computing systems,communications devices, networks and/or digital/logic devices foroperation. Each may, in turn, be configurable to utilize a suitablecomputing device which can be manufactured with, loaded with and/orfetch from some storage device, and then execute, instructions thatcause the computing device to perform a method according to aspects ofthe disclosed subject matter.

A computing device can include without limitation a mobile user devicesuch as a mobile phone, a smart phone and a cellular phone, a personaldigital assistant (“PDA”), such as an iPhone®, a tablet, a laptop, andthe like. In at least some configurations, a user can execute a browserapplication over a network, such as the Internet, to view and interactwith digital content, such as screen displays. A display includes, forexample, an interface that allows a visual presentation of data from acomputing device. Access could be over or partially over other forms ofcomputing and/or communications networks. A user may access aweb-browser, e.g., to provide access to applications and data and othercontent located on a web-site or a web-page of a web-site.

A suitable computing device may include a processor to perform logic andother computing operations, e.g., a stand-alone computer processing unit(“CPU”), or hard wired logic as in a microcontroller, or a combinationof both, and may execute instructions according to its operating systemand the instructions to perform the steps of the method, or elements ofthe process. The user's computing device may be part of a network ofcomputing devices and the methods of the disclosed subject matter may beperformed by different computing devices associated with the network,perhaps in different physical locations, cooperating or otherwiseinteracting to perform a disclosed method. For example, a user'sportable computing device may run an app alone or in conjunction with aremote computing device, such as a server on the Internet. For purposesof the present application, the term “computing device” includes any andall of the above discussed logic circuitry, communications devices anddigital processing capabilities or combinations of these.

Certain embodiments of the disclosed subject matter may be described forillustrative purposes as steps of a method which may be executed on acomputing device executing software. Included are software programcode/instructions that can be provided to the computing device or atleast abbreviated statements of the functionalities and operationsperformed by the computing device in executing the instructions. Somepossible alternate implementation may involve the function,functionalities and operations occurring out of the order, includingoccurring simultaneously or nearly so, or in another order or notoccurring at all. Aspects of the disclosed subject matter may beimplemented in parallel or seriatim in hardware, firmware, software, orany combination(s) of these, co-located or remotely located, at least inpart, from each other, e.g., in arrays or networks of computing devices,over interconnected networks, including the internet, and the like.

The instructions may be stored on a suitable “machine readable medium”within a computing device or in communication with or otherwiseaccessible to the computing device. As used in the present application amachine-readable medium is a tangible storage device and theinstructions are stored in a non-transitory way. At the same time,during operation, the instructions may at some times be transitory,e.g., in transit from a remote storage device to a computing device overa communication link. However, when the machine readable medium istangible and non-transitory, the instructions will be stored, for atleast some period of time, in a memory storage device, such as a randomaccess memory (RAM), read only memory (ROM), a magnetic or optical discstorage device, or the like, arrays and/or combinations of which mayform a local cache memory, e.g., residing on a processor integratedcircuit, a local main memory, e.g., housed within an enclosure for aprocessor of a computing device, a local electronic or disc hard drive,a remote storage location connected to a local server or a remote serveraccess over a network, or the like. When so stored, the software willconstitute a “machine readable medium,” that is both tangible and storesthe instructions in a non-transitory form. At a minimum, therefore, themachine readable medium storing instructions for execution on anassociated computing device will be “tangible” and “non-transitory” atthe time of execution of instructions by a processor of a computingdevice and when the instructions are being stored for subsequent accessby a computing device.

EXAMPLES

Sepsis

Another example of an application of the disclosed technology isdirected to an alternative process for continuous re-evaluation andadjustment of the PI zero. Many potentially useful applications of thedisclosed apparatus and methods will start when the monitored subject isnot in a healthy, resting state. For example, at the initialpresentation of a patient with early sepsis to a hospital emergencydepartment, there is likely already a significant pathologic decrease ofthe blood perfusion to the skin, resulting in the skin tissue statusbeing within the person's previous anaerobic range; i.e. negative PIvalue. Simply using the presenting abnormal physiologic conditions toset the PI zero will result in an indeterminate negative deviation ofthe PI zero relative to that person's previous healthy, resting PI zero.As effective treatment is administered, and the patient's physiologicstatus improves back toward normal health, the transition betweennegative PI and positive PI values, i.e. the PI zero, will migrateupward until it stabilizes at the patient's true normal level. Tocontinuously monitor and adapt to movement of this transition, a“finding PI zero” algorithm can be applied, whereby the relative changesof the red and IR intensity signals are used to repeatedly determinewhen the current PI value crosses the transition; i.e. the actual PIzero. For example, if the IR signal is unchanged, but the red signalprogressively increases in value as a result of effective therapy, thesubject is currently still in the negative PI range, but is approachingPI zero. As the physiologic condition continues to improve towardnormal, a new PI zero will be defined as: ‘when the red signal valuebecomes stable, while the IR signal begins to decrease in value.’ Asthis transition is detected, the fixed bias value will be updated to thecurrent offset between the red and IR signal values, bringing thecalculated PI value to the updated zero.

Premature Infants

As another example, moments before birth, a premature newborn infantwill be fully acclimated to the much lower fetal blood oxygen saturationranging from as low as about 10% up to as high as about 60%, withcorresponding relatively low fetal tissue oxygen delivery rate, relativeto the eventual rate of oxygen delivery to tissue during air-breathinglife. Current medical practice uses “blood gas” (SaO₂) measurements ofthe newborn infant's arterial blood and pulse oximetry (SpO₂)measurements to guide the oxygen fraction blending of breathing gasduring initial care of premature infants following birth. Monitoring ofskin tissue oxygen tension, using a Clark electrode sensor, is also anaccepted way of guiding oxygen delivery in the medical care of prematureinfants. Most recently, use of infrared light has enabled non-invasivemeasurement of the hemoglobin/oxygen saturation of the combination ofarterial, capillary, and venous blood deep within the infant's brain, asan index of the adequacy of blood perfusion and oxygen delivery to thebrain. The guiding assumption with the use of these instruments andassociated current practices, is that low blood oxygen (hypoxemia) andresulting low tissue oxygen level (tissue hypoxia), is the root cause ofthe unique and devastating vital organ tissue injuries encountered bypremature infants. However, current research literature is reportingthat the initial injury that occurs in these tissues is to theendothelial cells lining the post-capillary venules. Also recentlyreported is that these injuries are directly associated with an abruptonset of a relatively excessive oxygen delivery rate. Death anddisintegration of these venule endothelial cells triggers blood clottingand results in blockage of blood flow through their respectivecapillaries and, ultimately, the death of the tissues supplied by thosecapillaries. Unfortunately, blood oxygen measurements cannot indicatewhen the oxygen delivery rate exceeds the tolerance level of these verysensitive endothelial cells. Assuming normal lung function is rapidlyestablished as a result of immediate treatment using lung surfactant,breathing normal 20.8% oxygen fraction air has been consistentlyobserved to raise the infant's arterial blood oxygen saturation above80%, or even as high as 90%, which is far higher than ever occurs withfetal blood from the placenta. Aggravating this situation is the knownlower production of tissue-protective antioxidants, such as glutathione,in infants less than about 30 weeks' gestation. Thus, with less thanadequate tissue antioxidant protection, these infants are at risk ofsuffering hyperoxic injury to the microvascular endothelium in thebrain, gut, and eyes when these organs are suddenly perfused with muchhigher oxygen content blood, compared with the fetal environment momentsbefore birth. Until the discovery of the PI signal, there has been nomethod of detecting when tissues are receiving less than enough oxygen,just the right amount of oxygen, or too much oxygen relative to theircurrent need and capacity to safely utilize oxygen.

Newborns

In a similar example with premature infants, the full gestation infant'sinitial PI zero is also expected to start at a lower blood oxygen levelthan it will transition to become when the infant's tissues have hadtime to adapt to the higher oxygen availability of air-breathing life.In the case of full-term infants in distress from a variety ofcomplications of birth, the infant's breathing gas may also be moresafely started with a sub-atmospheric oxygen fraction, such as 15%.Then, as the infant's tissue oxygen need and oxygen tolerance graduallyincreases, the PI monitor may provide a surrogate index for vital organoxygen need and tolerance. It is anticipated that early evidence of thisadaptation will be seen when the red signal intensity begins to decreaserelative to a stable IR signal intensity, indicating the need for anincrease in the oxygen fraction in the breathing air until the redsignal remains stable, and the IR signal level begins to decrease; thusidentifying the new PI zero. A new fixed offset value will then beestablished, defining this updated PI zero. Note that thesedeterminations and breathing gas oxygen fraction changes are essentiallyindependent of the infant's arterial blood hemoglobin/oxygen saturationlevel. Blood oxygen measurements relate only to the efficiency of thelungs and blood as oxygen transport agents and cannot specificallyindicate whether vital organ tissues are being safely and effectivelysupplied with oxygen. The tissue injuries, especially those caused by anexcessive rate of tissue oxygen delivery, occur in the vital organs ofnewborn infants, and not in their blood. The disclosed PI monitoringapparatus and method, coupled with the PI monitoring-enabled regulationof breathing oxygen fraction disclosed herein, present a potentiallysafer and more effective initial care process compared with guidancebased on blood oxygen metrics.

Exercise

Still another aspect of the disclosure is directed to physiologicsensors that are configured to detect, using two-, or multi-wavelengthphotonic signal variation, a skin microcirculatory and/or skin tissuemetabolic chemistry response to muscular exertion, such as occurs withrecreational exercise, weight loss exercise, athletic training andperformance, or occupational work, etc.; as a surrogate index for thetotal body physiologic load presented by the muscular activity.Additionally, the disclosed sensors can be configured to show theobserved PI signal baseline shift response pattern thought to indicatethe rate of onset of fatigue apparently associated with the combinationof the extent of mechanical work output and the duration of theexertion. Current research relative to exercise regimens designed forathletic training, general health maintenance, rehabilitation followinginjury or surgery, and obesity weight loss, advocates the need forexercise sessions to be accurately designed for each individual suchthat the exercise can be both safe and effective in achieving thedesired goals. The new physiologic information provided by the disclosedPI sensors can be used to help optimize individual exercise regimenstoward achieving the safety and performance goals. As an example, thebeginning phase of a weight-loss oriented exercise regimen designed fora 300-pound person in precarious health needs to initially uselow-impact exercise and minimize stress to the heart, so as to notinjure major weight-bearing joints or trigger a heart attack. At thesame time, however, the exercise regimen needs to measurably improvegeneral health status and achieve an efficient rate of loss of storedbody fat as a result of the person's investment in time, effort,emotional stress, and economic cost. The work load progression, exercisesession duration, and session repetition timing for such a person willalso need to accommodate individual preferences, or it risks not beingsustainable. Today's therapist/trainers must substitute experience-basedexpert opinion for needed, but missing, objective measurements oftissue-level physiology. Theoretically, based on current research data,using stored body fat as the major fuel source for a weight lossexercise regimen calls for extended, purely aerobic-level exertion,rather than multiple brief bouts of heavy work to exhaustion. Finally,the exercise regimen needs to generate the biological signal/s that willup-regulate the production of tissue enzyme systems needed to preparebody fat for energy conversion. Further, sufficient rest and recoverytime needs to be allowed prior to the next episode to fully capitalizeon the stimulated gains. Currently, return to baseline resting heartrate, and return to baseline beat-to-beat heart rate variability uponwaking in the morning, are used to gauge recovery from exercise. Whilethese population statistics-derived indices may reflect heart health,the newly discovered PI signal provides an objective, potentially morerelevant, individualized view of energy conversion chemistry, as asurrogate index of this process throughout the body. The sufficientrecovery period for each person could, as an example, be determined byevaluating their rate of PI value fatigue trend at their next exercisesession; with a more rapid PI baseline rise indicating insufficientrecovery. Until the discovery of the PI signal, there has not been aconvenient, non-invasive, objective method of indicating that a personis: (1) exercising within their aerobic window, (2) that at the end ofeach exercise session there is an effective biological signal generatedthat will up-regulate fat utilization enzyme processes, and (3) thatsufficient recovery time has elapsed before another session.

Hypothermia

In still another aspect of the disclosure, diffused light physiologicsensors are described that detect, by two-, or multi-wavelength photonicsignal variation, the skin microcirculatory and/or skin tissue chemicalreaction response to adverse conditions, such as hypothermia from coldexposure, progressive hyperthermia from excessive environmentaltemperature/humidity exposure, or adverse reaction to infused oringested pharmacologic chemicals, such as when anesthetic or otherpharmacologic or other potentially, or actually toxic agents have beenintroduced into the body, and during recovery from such conditions,influences and reactions; as a surrogate index of reflex responsesprotective of vital organ tissues.

Tissue Ischemia

Additional aspects of the disclosure include physiologic sensors thatare configurable to detect, by two-, or multi-wavelength photonic signalvariation, the tissue microcirculatory and/or tissue chemical reactionresponse during re-perfusion following tissue ischemia, such as ispurposefully used during orthopedic surgery to achieve a bloodlesssurgical field, or, in general, as happens with return of bloodperfusion to body parts or organs that have been temporarilyunder-perfused, or not perfused; for the purpose of monitoring that theamount of oxygen delivered by the circulating blood to the re-perfusedtissue does not exceed that tissue's temporarily diminished, andgradually recovering, capacity to utilize the delivered oxygen; therebyhelping to optimize therapy. Related examples could includeresuscitation and recovery from central nervous system ischemic strokeand resuscitation following prolonged episodes of hypoxemia due tosuffocation, near-drowning, cardiac and/or respiratory arrest. Currenttherapy often includes a period of induced total body cooling, orhypothermia and/or pharmacologic-induced coma, to slow the metabolism ofthe brain. The remarkable success of hypothermia and induced comatherapies indicates, among other factors, that the most sensitivetissues in the brain can survive relatively long periods at lower oxygenlevels, but need time to up-regulate their capacity to utilize andtolerate delivery of oxygen at normal SpO₂ and perfusion levels. Forexample, since the less vital body tissues, such as the bones, muscles,and skin, more easily tolerate lowered oxygen delivery, the breathinggas oxygen fraction could be lowered gradually, with cardiac monitoring,to bring the patient's SpO₂ down to the 65-70% range for about 30minutes. This would allow the skin to acclimate to the lower level ofoxygen supply, as it has been recorded to do by recording PI sensor dataduring periods of exercise. This skin acclimation process is also anormal part of adapting to living at a higher altitude. As thisacclimation occurs, the “finding PI zero” algorithm will re-establish PIzero at the lower SpO₂ level. Then, since the skin serves as a perfusionbuffer to more vital organs, it may be monitored as a surrogate of morevital organs, with the PI sensor used to guide the gradual upwardadjustment of the oxygen fraction in the breathing gas. Theoretically,if organs more vital than the skin begin to need increased amounts ofoxygen, the skin will become more anaerobic as the autonomic nervoussystem diverts skin perfusion to these more vital organs, as it doesduring exercise and septic shock. Thus, when the PI value goes morenegative, indicating perfusion diversion to more vital organs, thebreathing oxygen fraction can be increased to bring the PI value back upto zero; and this cycle repeated until the person is breathingatmospheric oxygen fraction.

While preferred embodiments of the present invention have been shown anddescribed herein, it will be obvious to those skilled in the art thatsuch embodiments are provided by way of example only. Numerousvariations, changes, and substitutions will now occur to those skilledin the art without departing from the invention. It should be understoodthat various alternatives to the embodiments of the invention describedherein may be employed in practicing the invention. It is intended thatthe following claims define the scope of the invention and that methodsand structures within the scope of these claims and their equivalents becovered thereby.

What is claimed is:
 1. A physiologic index sensor comprising: a firstmeans for emitting a first wavelength wherein the first means foremitting the first wavelength is configurable to emit a first targetwavelength of from 650 nm to 670 nm into an epidermis layer and a dermislayer of a user; a second means for emitting a second wavelength whereinthe second means for emitting the second wavelength is configurable toemit a second target wavelength of from 840 nm to 860 nm into theepidermis layer and the dermis layer of the user; a detection meansoptically isolated from the first means for emitting the firstwavelength and the second means for emitting the second wavelengthwherein the detection means is configured to detect a first diffusedwavelength and a second diffused wavelength; a processor meansconfigured to perform an initialization process to determine a a secondpower level of the second means for emitting a second wavelength havinga second detected signal intensity less than the first detected signalintensity; subsequently operate the first means for emitting and thesecond means for emitting at the first power level and the second powerlevel, respectively, and receive an input from the detection means;further wherein the processor means is configured to calculate anoxygen-related energy conversion metabolism from the input and determinea tissue oxygen requirement; and a power source.
 2. The physiologicindex sensor of claim 1 wherein the physiologic index sensor furthercomprises a data transmitter means.
 3. The physiologic index sensor ofclaim 1 wherein the physiologic index sensor is configurable todetermine one or more of an index of oxygen delivery and aerobic energyconversion.
 4. The physiologic index sensor of claim 1 furthercomprising a housing means having a first aperture and a secondaperture.
 5. The physiologic index sensor of claim 4 wherein the firstaperture and the second aperture are filled with an optically clearmaterial.
 6. The physiologic index sensor of claim 4 further comprisinga securer means configured to secure the physiologic index sensor to anarm or a chest of the user.
 7. The physiologic index sensor of claim 1further comprising one or more electrically conductive skin contactadhesive means.
 8. The physiologic index sensor of claim 1 wherein atleast one of the first means for emitting the first wavelength and thesecond means for emitting the second wavelength is connected to aphysiologic index sensor housing via a cable.
 9. The physiologic indexsensor of claim 1 wherein at least one of the first means for emittingthe first wavelength and the second means for emitting the secondwavelength is an unfiltered broadband light source, using optical fibercables for light conveyance to and from the skin, and the detectionmeans is a spectrometer, with selected wavelength intensity valuesobtained by the spectrometer used to compute the physiologic index. 10.A physiologic index sensor comprising: a first emitter for emitting afirst wavelength wherein the first emitter for emitting the firstwavelength is configurable to emit a first target wavelength of from 650nm to 670 nm into an epidermis layer and a dermis layer of a user; asecond emitter for emitting a second wavelength wherein the secondemitter for emitting the second wavelength is configurable to emit asecond target wavelength of from 840 nm to 860 nm into the epidermislayer and the dermis layer of the user; a detector optically isolatedfrom the first emitter and the second emitter wherein the detector isconfigured to detect a first diffused wavelength and a second diffusedwavelength; a processor configured to perform an initialization processto determine first power level of the first emitter having a firstdetected signal intensity of about 80% of a sensor system A/D convertedmaximum count limit and a second power level of the second emitterhaving a second detected signal intensity less than the first detectedsignal intensity; subsequently operate the first emitter and the secondemitter at the first power level and the second power levelrespectively, and receive an input from the detector wherein theprocessor is configured to calculate an oxygen-related energy conversionmetabolism from the input and determine a tissue oxygen requirement,and; a power source.
 11. The physiologic index sensor of claim 10wherein the physiologic index sensor further comprises a datatransmitter.
 12. The physiologic index sensor of claim 10 wherein thephysiologic index sensor is configurable to determine one or more of anindex of oxygen delivery and aerobic energy conversion.
 13. Thephysiologic index sensor of claim 10 further comprising a housing havinga first aperture and a second aperture.
 14. The physiologic index sensorof claim 13 wherein the first aperture and the second aperture arefilled with an optically clear material.
 15. The physiologic indexsensor of claim 13 further comprising a securer configured to secure thephysiologic index sensor to an arm or a chest of the user.
 16. Thephysiologic index sensor of claim 10 further comprising one or moreelectrically conductive skin contact adhesive pads.
 17. The physiologicindex sensor of claim 10 wherein at least one of the first emitter foremitting the first wavelength and the second emitter for emitting thesecond wavelength is connected to a physiologic index sensor housing viaa cable.
 18. The physiologic index sensor of claim 10 wherein at leastone of the first emitter for emitting the first wavelength and thesecond emitter for emitting the second wavelength is an unfilteredbroadband light source, with two or more wavelength intensity valuesbeing selected by a spectrometer to be used to compute a physiologicindex value.
 19. A physiologic index sensor comprising: a housingadapted to engage a chest or an arm of a user wherein the housing has afirst aperture and a second aperture; a first emitter wherein the firstemitter is configurable to emit a first wavelength through the firstaperture into an epidermis layer and a dermis layer of the user; asecond emitter wherein the second emitter is configurable to emit asecond wavelength through the first aperture into the epidermis layerand the dermis layer of the user; a detector disposed within the housingwherein the detector is optically isolated in the housing from the firstemitter and the second emitter and adjacent the second aperture andfurther wherein the detector is configured to detect a first wavelengthdiffused through the epidermis layer and the dermis layer and a secondwavelength diffused through the epidermis layer and the dermis layer; aprocessor configured to perform an initialization process to determine afirst power level of the first emitter having a first detected signalintensity of about 80% of a sensor system A/D converted maximum countlimit and a second power level of the second emitter having a seconddetected signal intensity less than the first detected signal intensity;subsequently operate the first emitter and the second emitter at thefirst power level and the second power level, respectively, and receivean input from the detector wherein the processor is configured tocalculate an oxygen-related energy conversion metabolism from the inputand determine a tissue oxygen requirement; and a power source.
 20. Thephysiologic index sensor of claim 19 wherein the physiologic indexsensor further comprises a data transmitter.
 21. The physiologic indexsensor of claim 19 wherein the physiologic index sensor is configurableto determine one or more of an index of oxygen delivery and aerobicenergy conversion.
 22. The physiologic index sensor of claim 19 whereinthe first aperture and the second aperture are filled with an opticallyclear material.
 23. The physiologic index sensor of claim 19 furthercomprising a securer configured to secure the physiologic index sensorto the arm or the chest of the user.
 24. The physiologic index sensor ofclaim 19 wherein at least one of the first emitter for emitting thefirst wavelength and the second emitter for emitting the secondwavelength is connected to a physiologic index sensor housing via acable.
 25. The physiologic index sensor of claim 19 wherein at least oneof the first emitter for emitting the first wavelength and the secondemitter for emitting the second wavelength is an unfiltered broadbandlight source, with two or more wavelength intensity values beingselected by a spectrometer to be used to compute a physiologic indexvalue.
 26. A method of detecting a biological parameter comprising:placing a physiologic index sensor adapted to be in contact with an armor a chest of a patient wherein the physiologic index sensor furthercomprises, a first emitter for emitting a first wavelength into anepidermis layer and a dermis layer of a user wherein the first emitterfor emitting the first wavelength is configurable to emit a first targetwavelength of from 650 nm to 670 nm, a second emitter for emitting asecond wavelength into the epidermis layer and the dermis layer of theuser wherein the second emitter for emitting the second wavelength isconfigurable to emit a second target wavelength of from 840 nm to 860nm, a detector optically isolated from the first emitter and the secondemitter wherein the detector is configured to detect a first wavelengthdiffused through the epidermis layer and the dermis layer of the userand a second wavelength diffused through the epidermis layer and thedermis layer of the user, a processor configured to receive an inputfrom the detector; powering the physiologic index sensor with the powersupply; performing an initialization process to determine a first powerlevel of the first emitter having a first detected signal intensity ofabout 80% of a sensor system A/D converted maximum count limit and asecond power level of the second emitter having a second detected signalintensity less than the first detected signal intensity; emitting afirst light in the first wavelength and emitting a second light in thesecond wavelength at the first power level and the second power level,respectively; detecting the first light and the second light diffusedthrough the epidermis layer and the dermis layer; and analyzing thedetected light; calculating an oxygen-related energy conversionmetabolism and a tissue oxygen requirement from the detected light. 27.The method of claim 26 further comprising the step of determining anindex of oxygen delivery for the patient.
 28. The method of claim 26further comprising the step of transmitting data from the physiologicindex sensor to a second device.
 29. The method of claim 26 furthercomprising the step of detecting an excess oxygen level at a tissue. 30.A communication system, comprising: a physiologic index sensor adaptedto be in contact with an arm or a chest of a patient wherein thephysiologic index sensor further comprises, a first emitter for emittinga first wavelength into an epidermis layer and a dermis layer of thepatient wherein the first emitter for emitting the first wavelength isconfigurable to emit a first target wavelength of from 650 nm to 670 nm,a second emitter for emitting a second wavelength into the epidermislayer and the dermis layer of the patient wherein the second emitter foremitting the second wavelength is configurable to emit a second targetwavelength of from 840 nm to 860 nm, a detector optically isolated fromthe first emitter and the second emitter wherein the detector isconfigured to detect a first light diffused through the epidermis layerand the dermis layer and a second light diffused through the epidermislayer and the dermis layer, a processor configured to perform aninitialization process to determine a first power level of the firstemitter having a first detected signal intensity of about 80% of asensor system A/D converted maximum count limit and a second emitter atthe first power level and the second power level, respectively, andreceive an input from the detector and calculate an oxygen-relatedenergy conversion metabolism; a power supply in communication with thephysiologic index sensor to power the physiologic index sensor; a servercomputer system; a measurement module on the server computer system forpermitting a transmission of a measurement from the physiologic indexsensor over a network; and at least one of an API engine connected to atleast one of the physiologic index sensor to create a message about thecalculated oxygen-related energy conversion metabolism and transmit themessage over an API integrated network to a recipient having apredetermined recipient user name, an SMS engine connected to at leastone of a system for detecting physiological parameters and thephysiologic index sensor to create an SMS message about the measurementand transmit the SMS message over the network to a recipient devicehaving a predetermined measurement recipient telephone number, or anemail engine connected to at least one of the physiologic index sensorto create an email message about the measurement and transmit the emailmessage over the network to a recipient email having a predeterminedrecipient email address.
 31. The communication system of claim 30,further comprising a storing module on the server computer system forstoring the measurement in a physiologic index sensor server database.32. The communication system of claim 31, wherein the physiologic indexsensor is connectable to the server computer system over at least one ofa mobile phone network or an Internet network, and a browser on ameasurement recipient electronic device is used to retrieve an interfaceon the server computer system.
 33. The communication system of claim 32,further comprising: an interface on the server computer system, theinterface being retrievable by an application on a mobile device. 34.The communication system of claim 33, wherein the server computer systemis connectable over a cellular phone network to receive a response froma measurement recipient mobile device.
 35. The communication system ofclaim 30, further comprising: a downloadable application residing on ameasurement recipient mobile device, the downloadable applicationtransmitting a response and a measurement recipient phone number ID overa cellular phone network to the server computer system, the servercomputer system utilizing the measurement recipient phone number ID toassociate the response with an SMS measurement.